Definiens, ACD to develop RNA biomarker assays

Manjula Puthenedam, PhD, | | Health Imaging | Molecular Imaging
Advanced Cell Diagnostics (ACD), and Definiens have partnered to develop image analysis applications that will enable researchers to quantify RNA molecules in routine clinical specimens.

The partnership will build on ACD’s RNAscope platform and add new specialized image analysis solutions that will process and analyze images from RNAscope assays.

ACD’s RNAscope is an RNA in situ hybridization (ISH) method that can detect and quantify any expressed gene at single molecule sensitivity in individual cells in all major biological specimen types, said the Hayward, Calif. based company.

ACD will demonstrate the technology at American Association for Cancer Research (AACR) conference in Orlando, Fla., April 3 to 6.

Manjula Puthenedam, PhD,

Related Content

Dementia cases are about to skyrocket—how will this affect imaging demand?
Experts update AUC for amyloid, tau PET imaging for first time in more than a decade
Repurposed radiotracer lights up treatment-resistant tumors 'like a Christmas tree'
Researchers receive grant worth millions to develop portable PET scanner
Why is the US still dependent on foreign medical isotope production?
Downed high-flux reactor could restart sooner than anticipated

Around the web

Radiology Business
AI can help radiology standardize image exam data labeling

To fully leverage today's radiology IT systems, standardization is a necessity. Steve Rankin, chief strategy officer for Enlitic, explains how artificial intelligence can help.

Radiology Business
The biggest obstacles facing radiology business managers in 2025

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.